Friday, 25 October 2013

Serbia Pharmaceuticals and Healthcare Report Q4 2013

Business Monitor International Market Research Reports
Market Reports Online XML Feed 
Startup Hiring: How to Hire the Best People

Attract and retain the best people. 7 lectures from top founders and CEO's about how to hire for your startup! Sign up for $19.
From our sponsors
Serbia Pharmaceuticals and Healthcare Report Q4 2013
Oct 23rd 2013, 00:00

Price: $ 1295  

BMI View: Despite per capita expenditure on drugs increasing considerably towards the end of the last decade, Serbia's pharmaceutical market as a whole is underdeveloped in regional terms, having suffered as a result of political and economic instability.. As the country continues its economic convergence with developed Europe, drug consumption is also expected to rise. However, financial inefficiencies within the health insurance system mean that the National Health Insurance Institution (RZZO) is unable to always meet its obligations on time, with frequent changes to coverage and pharmaceutical pricing. Headline Expenditure Projections ? Pharmaceuticals: RSD81.38bn (US$0.93bn) in 2012 to RSD90.97bn (US$1.10bn) in 2013; +11.8% in local currency terms and +18.9% in US dollar terms. Forecast ...

Complete report details with Table of Contents and more @ http://www.marketreportsonline.com/286354.html

Delicious Digg Evernote Facebook Google Bookmarks Google Plus LinkedIn StumbleUpon Tumblr Twitter
You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

No comments:

Post a Comment